(NewsDirect)
Faron Pharmaceuticals Limited (AIM:FARN,OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warnerfrom Proactive London after the clinical stage biopharmaceuticalcompany revealed fresh data from the company's ongoing phase I/IItrial.
Its BEXMAB study isevaluating the efficacy of bexmarilimab in treating acute myeloidleukaemia (AML) and myelodysplastic syndromes (MDS). Jalkanen explainsthat the results show that bexmarilimab achieved a 50% remission rateamong 22 patients who had relapsed or were refractory to standardtreatments, including hypomethylating agents (HMAs). Of the 22patients, eight achieved complete remission, indicating that theirsymptoms were entirely eradicated or significantlyreduced.
Looking forward, he says the results "mean that theprogram we have been planning to take the clinical development all theway to the marketing approval, and we have said that we could actuallyfile the PLA in 2025. These results really support that view...I'm anticipating not to have really huge massive clinical trialsize any more for this project - we're probably looking at 50-100patients all in."
Contact Details
ProactiveUK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.